Fortress Biotech Inc. (NASDAQ: FBIO) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT FORTRESS BIOTECH INC.

Fortress Biotech Inc. (NASDAQ: FBIO)
Listen to this Section


$2.65
-0.1250 ( -4.51% ) 224.8K

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Clinical Trial Pipeline Stages


Drug Name Stage
TriplexDetailsCytomegalovirus Phase 2
DotinuradDetailsChronic refractory gout Phase 1b
CEVA-101DetailsTraumatic brain injury Failed

Market Data


Open $2.65
Previous Close $2.77
Volume 224.8K
Market Cap $86.70M
Day Range $2.65 - $2.82
52 Week Range $1.70 - $4.53
Shares Outstanding 33.22M
Change % -4.51%
Net Change ▼ -0.1250
Insider Ownership -0.10%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2011
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -539,691.00

Date Type Amount Purchased Purchaser
2024-07-15 Buy 5000.00 ROSENWALD LINDSAY A MD
2024-07-12 Buy 500.00 Jin David
2024-07-11 Buy 5000.00 ROSENWALD LINDSAY A MD
2024-07-10 Buy 5000.00 ROSENWALD LINDSAY A MD
2024-07-01 Buy 20000.00 ROSENWALD LINDSAY A MD
2024-06-28 Sale -575191.00 Fortress Biotech, Inc.

SEC Filings


Form Type Description Pages Date
8-k 8K-related 13 Nov 17, 2025
4 Insider transactions 1 Oct 02, 2025
8-k 8K-related 16 Oct 01, 2025
4 Insider transactions 1 Oct 01, 2025
8-k 8K-related 15 Aug 14, 2025
10-q Quarterly Reports 104 Aug 14, 2025
8-k 8K-related 13 Jul 16, 2025
8-k 8K-related 13 Jun 23, 2025
8-k 8K-related 15 Jun 05, 2025

Latest News


× Before browsing our site, please accept our cookies policy